It also has become clear that both levels and activity of ER and PR are dramatically influenced by growth factor receptor (GFR) signaling pathways and that this crosstalk is a major determinant of both breast cancer progression and response to therapy [6,7]. The gene discussed is PGR; the disease is breast carcinoma.